BiotechTube

Tc99m tilmanocept

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Rheumatoid Arthritis

Conditions

Rheumatoid Arthritis

Trial Timeline

May 27, 2021 → Jan 21, 2022

NCT ID
NCT04947137

About Tc99m tilmanocept

Tc99m tilmanocept is a phase 2 stage product being developed by Navidea Biopharmaceuticals for Rheumatoid Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT04947137. Target conditions include Rheumatoid Arthritis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT04947137Phase 2Completed

Competing Products

20 competing products in Rheumatoid Arthritis

See all competitors
ProductCompanyStageHype Score
TilmanoceptNavidea BiopharmaceuticalsPhase 1
25
KPL-404 + PlaceboKiniksa PharmaceuticalsPhase 2
47
Baricitinib + Methotrexate + Baricitinib Placebo + MTX Placebo + Folic AcidEli LillyPhase 3
77
LY2127399Eli LillyPhase 3
77
Baricitinib + TNF InhibitorEli LillyApproved
85
CT-P17 SC AI (adalimumab)CelltrionPhase 3
77
Remsima IV + Remsima SCCelltrionPre-clinical
23
CT-P13 + RemicadeCelltrionPhase 3
77
CT-P47 + EU-approved RoActemraCelltrionPhase 3
77
InfliximabCelltrionPhase 3
77
CT-P13 SC Auto-Injector + Placebo Auto-InjectorCelltrionPhase 3
77
Rituximab, MTX, folic acidCelltrionPhase 1
33
CT-P10 + Rituxan + MabTheraCelltrionPhase 3
77
CT-P47 AI (tocilizumab) + CT-P47 PFS (tocilizumab)CelltrionPhase 3
77
CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13CelltrionPhase 3
77
rituximabCelltrionPhase 1
33
CT-P17 SC + Humira SCCelltrionPhase 3
77
AdalimumabCelltrionPre-clinical
23
InfliximabCelltrionPhase 3
77
MRA(Tocilizumab)Chugai PharmaceuticalPre-clinical
23

Other Products from Navidea Biopharmaceuticals

[18F]NAV4694Phase 3
69
LymphoseekPhase 3
69
LymphoseekPhase 3
69
NAV5001 + DaTscanPhase 3
69
NAV5001Phase 3
69